Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Treasury Shares (2022 - 2025)

Entrada Therapeutics has reported Treasury Shares over the past 4 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.3 million for Q4 2025, up 16.05% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 16.05% YoY), and the annual figure for FY2025 was $2.3 million, up 16.05%.
  • Treasury Shares for Q4 2025 was $2.3 million at Entrada Therapeutics, down from $2.4 million in the prior quarter.
  • Over the last five years, Treasury Shares for TRDA hit a ceiling of $2.7 million in Q1 2025 and a floor of $295104.0 in Q2 2022.
  • Median Treasury Shares over the past 4 years was $1.2 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Treasury Shares: tumbled 62.82% in 2024 and later soared 437.67% in 2025.
  • Entrada Therapeutics' Treasury Shares stood at $463964.0 in 2022, then soared by 173.4% to $1.3 million in 2023, then skyrocketed by 55.18% to $2.0 million in 2024, then rose by 16.05% to $2.3 million in 2025.
  • The last three reported values for Treasury Shares were $2.3 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.